drugset / Trial / NCT04131192

Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

NCT04131192

Phase 1 Terminated 13 enrolled Sunshine Lake Pharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.

Timeline

Start
2019-11-11
Primary completion
2021-09-09
Completion
2021-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Larotinib Unknown 200 mg
Subject Larotinib Unknown 250 mg
Subject Larotinib Unknown 300 mg